Compare Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) trades at $18.35 (market cap $58.74B), while iShares 20 Plus Year Treasury Bond ETF trades at $77.72 (market cap $47.61B). The key difference: Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) is the larger of the two by market cap, and Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) pays a 3.33% dividend while iShares 20 Plus Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) for 0 Days and iShares 20 Plus Year Treasury Bond ETF for 83 Days on average.
| TAK | TLT | |
|---|---|---|
Market Cap | $58.74B | $47.61B |
Volume | 3,110,994 | 49,263,490 |
Sector | Health | Fixed Income |
52-Week High | $19.05 | $92.06 |
52-Week Low | $13.23 | $77.11 |
Typical Hold Time | 0 Days | 83 Days |
Enterprise Value | $86.65B | — |
Dividend Yield | 3.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $77.145, down 0.17% amid a challenging bond market environment. The technical picture is bearish with moving averages signaling strong selling pressure, though oscillators are neutral. Recent news highlights Treasury yields reaching multi-decade highs, with the fund experiencing significant outflows and declining nearly 50% over five years as rising interest rates pressure long-duration bonds.
The outlook remains pressured by persistent high interest rates and inflation concerns. While current yields above 5% offer income appeal, further rate hikes or prolonged elevated rates could extend the downtrend. Key risks include Federal Reserve policy uncertainty and economic data volatility. Investors should weigh the income potential against continued price depreciation risk in the current macro environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)
Takeda is a Japanese pharmaceutical company developing medicines across areas including gastrointestinal disease, rare diseases, neuroscience, oncology, and plasma-derived therapies.
Read more on TAK →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
